Revenues for the first half of 2021 and update on AB Science’s activities
30/09/2021 – AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study
28/09/2021 – AB Science today announced that a new clinical trial with masitinib in patients with symptomatic mild and moderate COVID-19 has been approved by the Regulatory Authorities of Russia and South Africa
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia
22/09/2021 – AB Science today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada
Abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
20/09/2021 – AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
Authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19
16/09/2021 – AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
New authorizations to resume patient enrollment in Phase 3 studies of masitinib
14/09/2021 – AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
Results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
13/09/2021 – AB Science today announced that results from masitinib study AB12003 in metastatic castrate refractory prostate cancer, have been presented as a podium presentation at the 2021 American Urological Association
Latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
02/09/2021 – AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND